New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
March 21 2022 - 8:01AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that
an analysis of sotagliflozin data from the SCORED Phase 3 clinical
trial will be presented as a late-breaker at the American College
of Cardiology’s 71st Annual Scientific Session (ACC.22). The
conference will be held on April 2-4, 2022, in person at the Walter
E. Washington Convention Center in Washington, DC, and virtually.
The new secondary analysis will be presented by
Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional
Cardiovascular Programs at Brigham and Women’s Hospital, professor
of medicine at Harvard Medical School, and study chair for the
SCORED trial. The presentation is entitled, “Sotagliflozin
Significantly Reduces Cardiovascular Death, Myocardial Infarction,
and Stroke in the SCORED Trial.”
The presentation will take place during Featured
Clinical Research I Session 403 on Saturday, April 2 at 12:00 pm
ET. Additional information on the presentation can be found
here.
About Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an investigational oral dual
inhibitor of two proteins responsible for glucose regulation known
as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
SGLT1 is responsible for glucose absorption in the gastrointestinal
tract, and SGLT2 is responsible for glucose reabsorption by the
kidney. Sotagliflozin is approved in the European Union (EU) for
use as an adjunct to insulin therapy to improve blood sugar
(glycemic) control in adults with type 1 diabetes with a body mass
index ≥ 27 kg/m2, who could not achieve adequate glycemic control
despite optimal insulin therapy, but has not yet been commercially
launched.
About Lexicon
Pharmaceuticals
Lexicon is a biopharmaceutical company with a
mission of pioneering medicines that transform patients’ lives.
Through its Genome5000™ program, Lexicon scientists studied the
role and function of nearly 5,000 genes and identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. Lexicon advanced
one of these medicines to market and has a pipeline of promising
drug candidates in discovery and clinical and preclinical
development in heart failure, neuropathic pain, diabetes and
metabolism and other indications. For additional information,
please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, including the
clinical development of, regulatory filings for, and potential
therapeutic and commercial potential of sotagliflozin, LX9211 and
its other potential drug candidates. In addition, this press
release also contains forward looking statements relating to
Lexicon’s growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully conduct preclinical and clinical development and
obtain necessary regulatory approvals of sotagliflozin, LX9211 and
its other potential drug candidates on its anticipated timelines,
successfully commercialize any products for which it obtains
regulatory approval, achieve its operational objectives, obtain
patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates. Any of these risks, uncertainties and
other factors may cause Lexicon’s actual results to be materially
different from any future results expressed or implied by such
forward-looking statements. Information identifying such important
factors is contained under “Risk Factors” in Lexicon’s annual
report on Form 10-K for the year ended December 31, 2021, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Investor Relations(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024